Wegovy contains semaglutide, a GLP-1 receptor agonist used at higher weekly doses for weight management. It helps reduce appetite and supports lower energy intake alongside everyday habits like balanced eating and movement. What semaglutide actually is Semaglutide is a medicine that mimics GLP-1 (glucagon-like peptide-1), a natural hormone in the body. GLP-1 plays a key role in appetite and metabolism: it slows the emptying of the stomach, enhances the release of insulin when

Wegovy and Ozempic share the same active ingredient (semaglutide), but they’re licensed for different uses and doses — Wegovy for weight...

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both effective; some studies show larger average weight loss with tirzepatide, but individual response, side-effects, access, and clinical goals matter. The “better” choice is the one that fits your health needs and tolerability after a clinician review. Two medicines, two mechanisms Wegovy and Mounjaro both belong to a family of medicines that mimic natural gut hormones involved in appetite and metabolism. Wegovy contains s

Wegovy isn’t licensed in the UK to treat fatty liver or other conditions directly, but weight reduction can improve liver fat and broader...

Storage is straightforward: keep pens in the refrigerator in their original carton, and do not freeze. Protect from light and check the...

Wegovy is a once-weekly subcutaneous injection given into the abdomen, thigh, or upper arm. Rotate sites each week and avoid areas that...

The duration is guided by your response, tolerability, and local commissioning policy. Services typically build in review points — for example, at six months and at later milestones — to check progress and decide on continuation. Some pathways set a maximum course length; others allow ongoing use if agreed benchmarks are met within specialist care. Your team will set expectations clearly at the start so you know how and when decisions will be made. Why duration is not the sam

There isn’t a one-off loading dose; instead there’s a gradual dose-escalation (titration) phase. You start low and step up in stages...

After stopping, many people regain some weight over time because appetite signals gradually return toward baseline. How much and how quickly varies, but the pattern is common across all weight-management approaches. Planning ahead helps: keep protein intake consistent, maintain activity that preserves strength, and agree a follow-up plan with your team (for example, a slower taper, maintenance strategies, or alternative support). If you stop because goals have been met, expec

In UK services, routine age use focuses on adults within specialist pathways. Use in people under 18 is specialist and not part of standard adult commissioning routes. If a young person is being considered for treatment, this would happen in paediatric services with multidisciplinary input and careful assessment of risks and benefits. Focus on adults in UK guidance In the UK, Wegovy is commissioned primarily for adults who meet strict eligibility criteria. NICE guidance and c

Clinically important interactions are few, but there are practical considerations. Because Wegovy can slow stomach emptying, the...

Wegovy was developed by Novo Nordisk as a higher-dose formulation of the GLP-1 receptor agonist semaglutide for chronic weight management, building on earlier experience with semaglutide for type 2 diabetes. Its evidence base comes from large, international STEP trials focused on weight and related health markers, with additional research exploring cardiovascular and kidney outcomes in selected groups. UK adoption is guided by national appraisals and commissioning policies; S

Combination weight loss medications aren’t routine in UK services because evidence for stacking treatments is limited and side-effect...

Wegovy does not “boost metabolism” in the thermogenic sense; its primary action is appetite regulation and reduced intake. As weight decreases, resting energy expenditure typically falls a little — that’s a normal adaptation seen with any weight loss. The meaningful advantage here is reduced hunger and cravings, which makes long-term behaviour change more realistic. Improvements in metabolic risk markers are observed in many users, but they stem from weight reduction and bett

The medicine is intended to sit alongside a reduced-calorie diet and regular movement, not replace them. People usually find it easier to meet protein targets, shrink portions, and cut between-meal snacking when appetite is quieter. Light-to-moderate activity protects muscle while weight comes down, and small daily habits (steps, resistance bands at home, shorter eating windows that suit you) compound gains without feeling punitive. UK services will tailor this mix and adjust

Appetite suppression with semaglutide comes from activating GLP-1 receptors in brain regions that govern hunger and satisfaction,...

Most people notice appetite shifts within the first few weeks, but visible results on the scale tend to appear gradually as the dose...

The dosage schedule is once weekly on the same day, using a step-up “titration” plan to reach a maintenance dose. A common pathway starts low (for example, 0.25 mg weekly) and increases in stages (0.5 mg → 1.0 mg → 1.7 mg) toward a usual maintenance dose of 2.4 mg weekly, with each step typically lasting several weeks. If side effects occur, clinicians can extend a step or pause before moving up; this flexibility is standard practice across UK services. People scheduled for p

The primary target is the GLP-1 receptor, found in brain regions that regulate hunger and satiety and in the gut’s signalling pathways....

The active ingredient is semaglutide. Everything else listed with the medicine are excipients — formulation components that stabilise the solution and help the injection work properly — but they do not contribute therapeutic activity. When people talk about Wegovy’s effect, they’re talking about semaglutide acting on GLP-1 receptors . Why semaglutide matters Semaglutide is the single therapeutic component in Wegovy. It belongs to a class of medicines called GLP-1 receptor ago